Recently Approved Drugs for Lowering and Controlling Intraocular Pressure to Reduce Vision Loss in Ocular Hypertensive and Glaucoma Patients

• Published in: Pharmaceuticals (Basel, Switzerland) Vol. 16; no. 6; p. 791
• Main Author: Sharif, Najam A
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26.05.2023; MDPI
• Subjects: Analysis; Blindness; Brain research; Care and treatment; Control; Drugs; Eye diseases; eye pressure; eyesight; Glaucoma; Growth factors; Homeostasis; Hypertension; Identification and classification; Inflammation; Intraocular pressure; ocular hypertension; Ophthalmic drugs; Optic nerve; Patient outcomes; Retinal diseases; Review; therapeutic modalities; Visual impairment; United States; Japan; eye pressure; microshunt; ocular hypertension; eyesight; intraocular pressure; drugs; therapeutic modalities; glaucoma; IOP-lowering
• ISSN: 1424-8247; 1424-8247
• DOI: 10.3390/ph16060791

Serious vision loss occurs in patients affected by chronically raised intraocular pressure (IOP), a characteristic of many forms of glaucoma where damage to the optic nerve components causes progressive degeneration of retinal and brain neurons involved in visual perception. While many risk factors abound and have been validated for this glaucomatous optic neuropathy (GON), the major one is ocular hypertension (OHT), which results from the accumulation of excess aqueous humor (AQH) fluid in the anterior chamber of the eye. Millions around the world suffer from this asymptomatic and progressive degenerative eye disease. Since clinical evidence has revealed a strong correlation between the reduction in elevated IOP/OHT and GON progression, many drugs, devices, and surgical techniques have been developed to lower and control IOP. The constant quest for new pharmaceuticals and other modalities with superior therapeutic indices has recently yielded health authority-approved novel drugs with unique pharmacological signatures and mechanism(s) of action and AQH drainage microdevices for effectively and durably treating OHT. A unique nitric oxide-donating conjugate of latanoprost, an FP-receptor prostaglandin (PG; latanoprostene bunod), new rho kinase inhibitors (ripasudil; netarsudil), a novel non-PG EP2-receptor-selective agonist (omidenepag isopropyl), and a form of FP-receptor PG in a slow-release intracameral implant (Durysta) represent the additions to the pharmaceutical toolchest to mitigate the ravages of OHT. Despite these advances, early diagnosis of OHT and glaucoma still lags behind and would benefit from further concerted effort and attention.